1. Home
  2. ALCYU vs BEATW Comparison

ALCYU vs BEATW Comparison

Compare ALCYU & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALCYU
  • BEATW
  • Stock Information
  • Founded
  • ALCYU N/A
  • BEATW 2015
  • Country
  • ALCYU
  • BEATW United States
  • Employees
  • ALCYU 3
  • BEATW 20
  • Industry
  • ALCYU
  • BEATW Retail: Computer Software & Peripheral Equipment
  • Sector
  • ALCYU
  • BEATW Technology
  • Exchange
  • ALCYU NYSE
  • BEATW Nasdaq
  • Market Cap
  • ALCYU N/A
  • BEATW N/A
  • IPO Year
  • ALCYU N/A
  • BEATW N/A
  • Fundamental
  • Price
  • ALCYU $11.48
  • BEATW $0.56
  • Analyst Decision
  • ALCYU
  • BEATW
  • Analyst Count
  • ALCYU 0
  • BEATW 0
  • Target Price
  • ALCYU N/A
  • BEATW N/A
  • AVG Volume (30 Days)
  • ALCYU N/A
  • BEATW 4.7K
  • Earning Date
  • ALCYU N/A
  • BEATW 03-14-2025
  • Dividend Yield
  • ALCYU N/A
  • BEATW N/A
  • EPS Growth
  • ALCYU N/A
  • BEATW N/A
  • EPS
  • ALCYU N/A
  • BEATW N/A
  • Revenue
  • ALCYU N/A
  • BEATW N/A
  • Revenue This Year
  • ALCYU N/A
  • BEATW N/A
  • Revenue Next Year
  • ALCYU N/A
  • BEATW N/A
  • P/E Ratio
  • ALCYU N/A
  • BEATW N/A
  • Revenue Growth
  • ALCYU N/A
  • BEATW N/A
  • 52 Week Low
  • ALCYU N/A
  • BEATW $0.50
  • 52 Week High
  • ALCYU N/A
  • BEATW $0.62
  • Technical
  • Relative Strength Index (RSI)
  • ALCYU 86.85
  • BEATW N/A
  • Support Level
  • ALCYU $11.07
  • BEATW N/A
  • Resistance Level
  • ALCYU $11.25
  • BEATW N/A
  • Average True Range (ATR)
  • ALCYU 0.00
  • BEATW 0.00
  • MACD
  • ALCYU 0.01
  • BEATW 0.00
  • Stochastic Oscillator
  • ALCYU 100.00
  • BEATW 0.00

About ALCYU ALCHEMY INVTS ACQUISITION CORP 1 UNIT 1 CL A COM & 1/2 WT

Alchemy Investments Acquisition Corp 1 is a blank check company.

About BEATW Heartbeam Inc.

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Share on Social Networks: